TD Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

TD Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-539	Closed	-$300K	–	1556
2021 Q3	$300K	Hold	539	–	–	﹤0.01%	1452
2021 Q2	$232K	Hold	539	–	–	﹤0.01%	1471
2021 Q1	$421K	Hold	539	–	–	﹤0.01%	1421
2020 Q4	$294K	Hold	539	–	–	﹤0.01%	1387
2020 Q3	$247K	Hold	539	–	–	﹤0.01%	1323
2020 Q2	$332K	Hold	539	–	–	﹤0.01%	1259
2020 Q1	$256K	Hold	539	–	–	﹤0.01%	1290
2019 Q4	$313K	Hold	539	–	–	﹤0.01%	1312
2019 Q3	$355K	Hold	539	–	–	﹤0.01%	1230
2019 Q2	$417K	Hold	539	–	–	﹤0.01%	1212
2019 Q1	$381K	Hold	539	–	–	﹤0.01%	1232
2018 Q4	$252K	Hold	539	–	–	﹤0.01%	1331
2018 Q3	$465K	Hold	539	–	–	﹤0.01%	1302
2018 Q2	$372K	Buy	539 +6	+1%	+$3.05K	﹤0.01%	1325
2018 Q1	$238K	Hold	533	–	–	﹤0.01%	1302
2017 Q4	$235K	Sell	533 -11	-2%	-$5.01K	﹤0.01%	1286
2017 Q3	$268K	Buy	544 +133	+32%	+$66.6K	﹤0.01%	1252
2017 Q2	$228K	Buy	+411	New	+$261K	﹤0.01%	1297

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

TD Asset Management's TVRD Position: Q4 2021 in Review

TD Asset Management sold out of Tvardi Therapeutics (TVRD) in Q4 2021, closing a stake of 539 shares — an estimated $300K sold.

TD Asset Management first reported a position in TVRD in Q2 2017 and held it in 18 quarters. The position peaked at $465K in Q3 2018. 180 funds tracked by Wall St. Rank hold TVRD as of Q4 2021.

TD Asset Management reported no remaining Tvardi Therapeutics position as of Q4 2021 after selling out during the quarter.
TD Asset Management sold 539 Tvardi Therapeutics shares in Q4 2021, an estimated $300K.
TD Asset Management first reported a position in Tvardi Therapeutics in Q2 2017 and held it in 18 quarters.
TD Asset Management's Tvardi Therapeutics position peaked at $465K in Q3 2018.
180 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2021.

Based on TD Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.